

## **Eurocor to present interim results of Freeway Stent Study at IROS Congress**

- **Freeway™ drug-eluting balloon for treatment of *de novo* lesions in the SFA or popliteal arteries**
- **Presentation of the interim results January 17th, 2013 in the Free Paper Session 2 from 4.30 – 5.15 pm**
- **Visit us at booth No. 30, Level B**

**Bonn, Germany – January 10, 2013** – Eurocor will be present at the IROS Congress in Berlin, Germany. The IROS Congress (Interventionell Radiologische Olbert Symposium, Dreiländer-Tagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Interventionelle Radiologie) will take place January 17th – 19th 2013. With approx. 800 participants in 2012, the IROS Congress has once again been established as the leading congress for professional further education in the sphere of vascular radiology in German-speaking countries.

Prof. J. Tacke (Klinikum Passau) will be presenting the Eurocor interim results of the first 100 patients on January 17th, 2013 in the Free Paper Session 2 from 4.30 pm – 5.15 pm.

The multicenter, open, prospective randomized trial investigates the prevention of restenosis by stenting with a Nitinol Stent followed by a drug-eluting balloon (DEB) [Freeway™](#) versus stenting with a Nitinol Stent with standard balloon (POBA) post dilatation in the treatment of Superficial Femoral Artery (SFA) or Popliteal artery (PI-segment) lesions in the legs.

The randomized, prospective clinical study is being conducted in 15 European sites to investigate the rate of clinically driven target lesion revascularization (TLR). 200 patients suffering from *de novo* lesions that need to be stented are enrolled and are randomized in a 1:1 ratio. Both groups will be treated with Nitinol stent implantation following postdilatation with a drug-eluting balloon (Freeway DEB) or a plain old balloon (POBA),



randomized in a 1:1 ratio. The Primary Endpoint is the rate of clinically driven target lesion revascularization (TLR) at 6 months.

Eurocor is looking forward to seeing you in Berlin.

**-End-**

**Media Contact**

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

**The Company:**

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.

For more information, please visit [eurocor.de](http://eurocor.de) and [optocircuits.com](http://optocircuits.com).